Abzena Establishes a Strategic Scientific Advisory Board
Abzena, a leader in integrated CDMO and CRO services for complex biologics, is excited to share the creation of its new Scientific Advisory Board (SAB). This board comprises experienced professionals from the biopharma industry, each offering diverse expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The establishment of this advisory board signals Abzena's dedication to fostering innovation and supporting its growth strategies effectively.
Driving Innovation Through Expertise
Matt Stober, the CEO of Abzena, expressed the strategic importance of this new board. He mentioned, "The formation of the Scientific Advisory Board is aimed at steering Abzena's future. We have observed significant progress in our ability to support intricate and innovative therapy modalities, including Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecific therapies. Our goal is to keep enhancing these capabilities, providing top-notch technologies to benefit our customers’ initiatives. These experts will play a vital role in refining our strategies and suggesting actions to further expedite the pathway of medicines to patients."
Industry Leaders Join the Board
Joe Principe, Abzena's Chief Commercial Officer, shared his enthusiasm in welcoming the SAB members, who are esteemed leaders within their respective fields. Principe stated, "These founding members have proven their prowess in the industry, and their guidance will be invaluable as we embark on this important growth phase. We eagerly anticipate their influence in bolstering our organization through their contributions."
Meet the Founding Members
Among the established professionals on the Scientific Advisory Board are:
John Knight, Ph.D., founder of a UK-based consulting firm offering pivotal services in process chemistry and CMC, aimed at enhancing early-stage chemical development and facilitating project transitions. With nearly four decades in pharmaceuticals, Dr. Knight has a wealth of experience, previously holding positions at GSK and other notable firms.Kamal Egodage, Ph.D., MBA, who leads Lasanth® Consulting, providing essential services from discovery to commercialization, focusing on CMC development and regulatory strategy. His extensive career includes significant contributions at top-tier companies such as Eli Lilly and Novartis, where he headed business development strategies for biologics.Morris Rosenberg, D.Sc., with over 25 years of experience in therapeutic agent development, offers consulting services focusing on biologics and ADC therapies. His key contributions include pivotal roles in the development of numerous industry-changing therapies.Scott Rudge, Ph.D., brings expertise from co-founding RMC Pharmaceutical Solutions and currently serves as a Principal Consultant at Syner-G. He has significant leadership experience in various biopharmaceutical sectors and is committed to advancing scientific and commercial strategies.
Steven Sandoval is the CEO and Operations Head at Pharmaceutical Technical Solutions, Inc. (PTSI), bringing over 30 years of biopharmaceutical experience to the table, specializing in manufacturing and CMC tech transfers.
Tatyana Touzova, the Chief Pharmaceutical Development & Manufacturing Officer at SERA Medicines, boasts over three decades of drug development expertise, overseeing critical operations from discovery to clinical stages.
About Abzena
Abzena stands as a premier bioconjugate and complex biologics CDMO + CRO, fully supporting the development of innovative treatments. The company is committed to collaborating with clients through integrated programs, focusing on mitigating risks and optimizing their development processes. With advanced facilities across several locations, Abzena excels in delivering tailored strategies that unlock the potential of therapeutic molecules, streamlining their progression to market. It is owned by Welsh, Carson, Anderson & Stowe, a recognized leader in private equity investment.
Frequently Asked Questions
What is the purpose of the Scientific Advisory Board at Abzena?
The Scientific Advisory Board is established to guide Abzena's innovation strategy and provide expert insights to enhance its growth.
Who are the key members of Abzena's Scientific Advisory Board?
The board includes industry leaders such as John Knight, Kamal Egodage, Morris Rosenberg, Scott Rudge, Steven Sandoval, and Tatyana Touzova.
How will the advisory board impact Abzena's operations?
By sharing their extensive industry knowledge, the advisory board members will help refine strategies that enhance the efficiency of moving medicines from concept to market.
What expertise do the board members bring to Abzena?
The members bring a wealth of experience in pharmaceuticals, regulatory strategy, product development, and commercialization, spanning several decades.
How does Abzena tailor its approach to clients?
Abzena customizes its strategies and services to meet the unique needs of each project, ensuring effective support throughout the development process.
